A5057664558- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Hemophilia Treatment and Research
- Autoimmune Bullous Skin Diseases
- Asthma and respiratory diseases
- Urticaria and Related Conditions
- Mast cells and histamine
- Vitamin K Research Studies
- Blood Coagulation and Thrombosis Mechanisms
- IL-33, ST2, and ILC Pathways
- Peptidase Inhibition and Analysis
- Enzyme function and inhibition
- Chronic Myeloid Leukemia Treatments
- NF-κB Signaling Pathways
- Monoclonal and Polyclonal Antibodies Research
- Drug-Induced Adverse Reactions
- PI3K/AKT/mTOR signaling in cancer
- Inflammatory mediators and NSAID effects
- Immune Cell Function and Interaction
- Respiratory and Cough-Related Research
- Eosinophilic Esophagitis
- Immune Response and Inflammation
- Allergic Rhinitis and Sensitization
- Cytokine Signaling Pathways and Interactions
- Pediatric health and respiratory diseases
- Complement system in diseases
University of California, San Diego
2016-2025
VA San Diego Healthcare System
2014-2025
UC San Diego Health System
2016-2024
United States Department of Veterans Affairs
2013-2023
Nia Association
2021
Universidad Católica Santo Domingo
2021
Parallax Research (United States)
2021
La Jolla Alcohol Research
1988-2020
San Francisco VA Medical Center
2008-2018
Istituto Nazionale di Fisica Nucleare, Sezione di Milano
2018
We published the Canadian 2003 International Consensus Algorithm for Diagnosis, Therapy, and Management of Hereditary Angioedema (HAE; C1 inhibitor [C1-INH] deficiency) updated this as angioedema: a current state-of-the-art review: Hungarian 2007 Angioedema. To update Therapy (circa 2010). The Network (CHAEN)/Réseau Canadien d'angioédème héréditaire (RCAH) http://www.haecanada.com cosponsors University Calgary Society Allergy Clinical Immunology (with an unrestricted educational grant from...
Angioedema is defined as localized and self-limiting edema of the subcutaneous submucosal tissue, due to a temporary increase in vascular permeability caused by release vasoactive mediator(s). When angioedema recurs without significant wheals, patient should be diagnosed have distinct disease. In absence accepted classification, different types are not uniquely identified. For this reason, European Academy Allergy Clinical Immunology gave its patronage consensus conference aimed at...
Synovial inflammation is often associated with systemic changes, such as increased levels of acute phase proteins and hypergammaglobulinemia, which cannot be explained by the cytokines described in synovial fluids synoviocyte secretions. Interleukin 6 (IL-6) has recently been characterized a mediator multiple inflammatory responses. This cytokine promotes T B lymphocyte growth differentiation, protein synthesis. We therefore examined IL-6 production human synoviocytes its presence fluids. In...
Abstract Hereditary Angioedema ( HAE ) is a rare and disabling disease. Early diagnosis appropriate therapy are essential. This update revision of the global guideline for provides up‐to‐date consensus recommendations management . In development this guideline, an international expert panel reviewed existing evidence developed 20 that were discussed, finalized consented during conference in June 2016 Vienna. The final version incorporates contributions board reviewers endorsing societies....
Hereditary angioedema due to C1 inhibitor deficiency is characterized by recurrent acute attacks of swelling that can be painful and sometimes life-threatening.
To cite this article: Cicardi M, Bork K, Caballero T, Craig Li HH, Longhurst H, Reshef A, Zuraw B on behalf of HAWK ( H ereditary A ngioedema International W or k ing Group). Evidence‐based recommendations for the therapeutic management angioedema owing to hereditary C1 inhibitor deficiency: consensus report an Working Group. Allergy 2012; 67 : 147–157. Abstract Angioedema deficiency (HAE) is a rare, life‐threatening, disabling disease. In last 2 years, results well‐designed and controlled...
Hereditary Angioedema (HAE) is a rare disease and for this reason proper diagnosis appropriate therapy are often unknown or not available physicians other health care providers. For we convened group of specialists that focus upon HAE from around the world to develop only consensus on management HAE, but also provide evidence based grades, strength classification consensus. Since both grading were adhered document meets criteria as guideline. The outcome guideline improve patients with...
Hereditary angioedema (HAE) is a rare and disabling disease for which early diagnosis effective therapy are critical. This revision update of the global WAO/EAACI guideline on management HAE provides up-to-date guidance HAE. For this guideline, an international panel experts reviewed existing evidence, developed 28 recommendations, established consensus by online DELPHI process. The goal these recommendations to help physicians their patients in making rational decisions with deficient C1...
Scientific and clinical progress together with the development of effective novel therapeutic options has engendered multiple important changes in diagnosis management hereditary angioedema (HAE). We now update extend 2013 United States Hereditary Angioedema Association Medical Advisory Board guidelines for treatment HAE. The are based on a comprehensive literature review recommendations indicating both strength our recommendation quality underlying evidence. Guidelines provided regarding...
Current treatments for long-term prophylaxis in hereditary angioedema have limitations.To assess the efficacy of lanadelumab, a fully human monoclonal antibody that selectively inhibits active plasma kallikrein, preventing attacks.Phase 3, randomized, double-blind, parallel-group, placebo-controlled trial conducted at 41 sites Canada, Europe, Jordan, and United States. Patients were randomized between March 2016, September 9, 2016; last day follow-up was April 13, 2017. Randomization 2:1...
Hereditary angioedema is a disabling, potentially fatal condition caused by deficiency (type I) or dysfunction II) of the C1 inhibitor protein. In phase 2 trial, use CSL830, nanofiltered preparation that suitable for subcutaneous injection, resulted in functional levels activity would be expected to provide effective prophylaxis attacks.We conducted an international, prospective, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, 3 trial evaluate efficacy and safety...
Chronic persistent asthma is characterized by ongoing airway inflammation and remodeling. The processes leading to remodeling are poorly understood, there increasing evidence that even aggressive anti-inflammatory therapy does not completely prevent this process. We sought investigate whether TGFβ1 stimulates bronchial epithelial cells undergo transition a mesenchymal phenotype, can be abrogated corticosteroid treatment or enhanced the pro-inflammatory cytokine IL-1β. BEAS-2B primary normal...
Galectin-7 is normally expressed in all types of stratified epithelia, but significantly down-regulated squamous cell carcinomas. This protein was recently found to be highly inducible by p53 a colon carcinoma line, DLD-1, and designated as PIG1 (for p53-inducedgene 1). We studied transfectants HeLa DLD-1 cells ectopically expressing this that they were more susceptible apoptosis than control transfectants. observed induced mechanistically distinct stimuli, suggesting galectin-7 acts on...
Abstract Crystal‐related joint diseases are often associated with systemic inflammatory manifestations, including increased levels of acute‐phase proteins, leukocytosis, and fever. Recently, interleukin‐6 (IL‐6) has been identified as a pluripotent mediator immunologic responses the major hepatocyte‐stimulating factor. In this study, we demonstrated that monosodium urate (MSU) calcium pyrophosphate dihydrate (CPPD) crystals, to lesser extent, hydroxyapatite IL‐6 production by synoviocytes...
Hereditary angioedema (C1 inhibitor deficiency, HAE) is associated with intermittent swellings which are disabling and may be fatal. Effective treatments available these most useful when given early in the course of swelling. The requirement to attend a medical facility for parenteral treatment results delays. Home therapy offers possibility earlier better symptom control, enabling patients live more healthy, productive lives. This paper examines evidence patient-controlled home acute...
A new form of hereditary angioedema (HAE) with normal C1 inhibitor (C1INH) was first described in 2000. The lack clear diagnostic criteria, the heterogeneity among affected patients, and varying names given to this disease have led substantial confusion both physicians patients. This study designed bring more clarity diagnosis potential treatment HAE C1INH. An international symposium experts convened review field develop consensus opinions that could help clinicians who evaluate manage these...